Core Insights - BD (Becton, Dickinson and Company) has expanded its respiratory and STI diagnostics offerings in Europe with the IVDR certification of two new VIASURE assays for the BD MAX™ System, enhancing the detection capabilities for a wide range of pathogens [1][2] Group 1: Product Expansion - The newly certified assays include a respiratory virus detection kit that identifies multiple viruses such as SARS-CoV-2, flu (A and B), RSV, and others from a single nasopharyngeal swab, and an assay for herpes simplex viruses and Treponema pallidum from skin lesion swabs [5][6] - The BD MAX™ System can process up to 24 samples per run and provides results in approximately three hours with less than one minute of hands-on time per sample, supporting timely and reliable clinical decision-making [2][4] Group 2: Strategic Partnership - The partnership with Certest Biotec, which began in 2017, has been crucial for BD in expanding its diagnostic menu and is expected to lead to further innovative projects in the future [3][6] - Certest Biotec specializes in the development and commercialization of in vitro diagnostic medical devices, contributing to BD's broad portfolio in human diagnostics [5][6] Group 3: Company Overview - BD is one of the largest global medical technology companies, focusing on improving medical discovery, diagnostics, and care delivery, with a commitment to enhancing safety and efficiency in healthcare [4] - The company employs over 70,000 individuals and collaborates with organizations worldwide to address significant global health challenges [4]

Core Insights - Anbio Biotechnology is actively participating in three major international exhibitions to expand its global presence in human and veterinary healthcare [1][5] - The company aims to meet the increasing demand for faster, more accurate, and decentralized testing solutions through its diversified portfolio and expanding global network [2][5] - Anbio's mission focuses on reshaping diagnostics through collaboration, innovation, and accessibility, as stated by its CEO [3][5] Company Strategy - Anbio has product registrations in over 100 countries and is pursuing a global strategy of innovation, collaboration, and commercialization [5][7] - The company is seeking distribution partners, research collaborators, and strategic investors to enhance diagnostic access and co-develop market-specific solutions [6][7] Product Offerings - Anbio's diagnostic portfolio includes Fluorescence Immunoassay (FIA) Systems, Dry Chemistry Analyzers, Rapid Test Kits, Molecular Diagnostic Systems, and a Veterinary Diagnostics Suite [8] - The FIA Systems support 90 test items for rapid and quantitative detection across various clinical areas [8] - Dry Chemistry Analyzers are designed for essential biochemical testing at the point of care, ideal for decentralized settings [8] - The Molecular Diagnostic System includes LAMP-based Rapid Mdx System and real-time RT-PCR reagents, enabling faster nucleic acid detection [8] - The Veterinary Diagnostics Suite integrates various diagnostic methods to support companion animal health needs [8]